We report a case of a vertically infected woman treated with darunavir/ritonavir plus a standard backbone before pregnancy. The analysis of darunavir/ritonavir concentrations in peripheral maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed low levels of darunavir in the mother and limited transfer across the placenta.
plus darunavir/ritonavir twice daily (600/100 mg). The woman started this regimen 18 months before pregnancy on the basis of HIV-1 resistance genotyping, and careful counselling was offered to continue these drugs during pregnancy. She was also receiving secondary prophylaxis for cryptococcosis with fluconazole. At the diagnosis of pregnancy, CD4 + T-cell count was 337 cells/ µl (17%) and plasma viral load was undetectable (HIV-1 RNA<50 copies/ml).
On the dates that drug pharmacokinetics were measured, she was instructed to complete a form reporting the exact timing of her last therapy dosing. Blood samples (5 ml) for determination of trough concentrations (C troughs ) were drawn immediately before dosing and 1, 2, 3 and 4 h post-dosing, before pregnancy, as well as at 26 and 36 weeks of gestation (before pregnancy the patient was enrolled in a darunavir pharmacokinetics study). Maternal and cord blood sampling were carried out at delivery (4 and 5 h after the last maternal drug administration, respectively). The determinations of plasma darunavir and ritonavir levels were carried out by HPLC technique with UV detection, according to a method previously described in detail for other antiretrovirals [2] . With regards to darunavir, the detection limit of the assay was 0.05 µg/ml, and the dynamic range was 0.05-10 µg/ml. Inter-and intrapatient variabilities, calculated on 90 pre-dose plasma samples (C trough ) in 49 patients, were 52.9% and 38.3%, respectively; these figures were lower than those for other tested PIs [2, 3] .
Caesarean Association guidelines [1, 4] ) was performed at 38 weeks of gestation; no adverse events were reported. CD4 + T-cell count at delivery was 452 cells/µl (18%) and plasma viral load was undetectable (HIV-1 RNA<50 copies/ml). Although the woman presented poor adherence to different PI-based regimens in the past, during pregnancy she had good compliance to antiretroviral medication, with consistently undetectable viral load. The newborn received a post-natal prophylactic antiretroviral regimen with zidovudine alone and three negative HIV-1 DNA PCR tests were obtained (at 0, 2 and 4 months of age).
Results of darunavir pharmacokinetics are illustrated in Figure 1 and the main parameters are summarized in Table 1 [5] . Darunavir C trough, 4-h concentration (C 4 h ) and 0-4 h area under the curve (AUC 0-4 h ) in the second and third trimester were 53% and 65%, 46% and 50%, and 43% and 46%, lower than those obtained before pregnancy, respectively. At delivery, the darunavir C 4 h was 3.59 µg/ml, lower than C 4 h levels obtained before pregnancy and at 26 and 36 weeks gestation. The ratio of cord blood to maternal blood darunavir concentration was 0.24. To date, the minimal effective concentration of darunavir has not been determined. Despite the significantly reduced darunavir exposure found in this patient during pregnancy as compared to her pre-pregnancy values, the trough and peak concentration found in this patient during pregnancy are still within the range of those observed in HIV-1-infected patients [6] and never fall below the median darunavir 50% inhibitory concentration for PI-resistant HIV-1 strains corrected for protein binding, which corresponds to 21 ng/ml [7] .
During pregnancy, maternal physiological changes (for example, gastrointestinal function, glomerular filtration rate, hepatic metabolism, cardiac output, maternal plasmatic protein level and total body mass) could modify drug absorption, distribution, biotransformation and elimination [8] [9] [10] . Plasma albumin and α-acid glycoprotein concentrations are also decreased during pregnancy (partly because of haemodilution), thus potentially reducing the protein binding of darunavir [11] . Therefore, the decreased drug exposure might be partially compensated by an increased proportion of free drug. Additional factors determining potential kinetic changes are represented by placental transport and biotransformation in the fetal compartment. In general, the pharmacokinetics of nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitor drugs are similar in pregnant and non-pregnant women [12] [13] [14] [15] , whereas PI pharmacokinetics are variable, particularly during late pregnancy. Several studies showed extremely low placental transfer of PIs (for example, saquinavir, nelfinavir and lopinavir/ ritonavir) [16] [17] [18] , with highly variable levels in both peripheral maternal and cord blood [16] [17] [18] [19] [20] [21] . Concerns remain about potential toxic effects on the mother and fetus, and about the development of resistance associated with incomplete virological suppression because of insufficient exposure [22, 23] . The curve shows data pre-dose and at 1, 2 and 4 h post-dose for the three phases studied, including before pregnancy and at 26 and 36 weeks of gestation.
Time point AUC 0-4 , µg•h/ml C trough , µg/ml C 4 h , µg/ml The rates of resistance are similar in pregnant and in non-pregnant HIV-1-infected women, especially among antiretroviral-experienced women. Rare cases of mother-to-child transmission of multidrug-resistant HIV-1 were reported, although the presence of resistance mutations does not increase the risk of transmission when current recommendations for antiretroviral management in pregnancy are followed.
Our data show a reduction of plasma levels of darunavir in pregnancy, in agreement with other studies on PI pharmacokinetics during pregnancy. The analysis of darunavir concentrations in maternal plasma throughout pregnancy, as well as in umbilical cord blood at delivery, showed decreased levels of darunavir in the mother and limited transfer across the placenta. Clinical implication of our observation and the potential effect on the development of drug resistance is uncertain. At 1 year post-delivery maternal HIV-1 RNA was still undetectable.
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